CELU vs. MVST, ATIP, LOTZ, CMAX, ENTA, IMMP, EBS, FHTX, ACRV, and XBIT
Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Microvast (MVST), ATI Physical Therapy (ATIP), CarLotz (LOTZ), CareMax (CMAX), Enanta Pharmaceuticals (ENTA), Immutep (IMMP), Emergent BioSolutions (EBS), Foghorn Therapeutics (FHTX), Acrivon Therapeutics (ACRV), and XBiotech (XBIT).
Microvast (NASDAQ:MVST) and Celularity (NASDAQ:CELU) are both small-cap business services companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
Celularity has lower revenue, but higher earnings than Microvast.
Microvast has a net margin of -29.79% compared to Microvast's net margin of -1,226.72%. Microvast's return on equity of 30.79% beat Celularity's return on equity.
Microvast presently has a consensus price target of $4.50, indicating a potential upside of 1,103.53%. Given Celularity's higher possible upside, equities analysts plainly believe Microvast is more favorable than Celularity.
Microvast has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.
20.7% of Microvast shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 31.3% of Microvast shares are owned by insiders. Comparatively, 20.7% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Celularity had 1 more articles in the media than Microvast. MarketBeat recorded 2 mentions for Celularity and 1 mentions for Microvast. Celularity's average media sentiment score of 0.93 beat Microvast's score of 0.44 indicating that Microvast is being referred to more favorably in the media.
Microvast received 2 more outperform votes than Celularity when rated by MarketBeat users. However, 42.11% of users gave Celularity an outperform vote while only 41.67% of users gave Microvast an outperform vote.
Summary
Microvast beats Celularity on 9 of the 15 factors compared between the two stocks.
Get Celularity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celularity Competitors List
Related Companies and Tools
